UroGen Pharma (URGN) Stock
UroGen Pharma (URGN) closed at $29.87 on Nov 17, 2026; its Tenet Score is 44 of 100 against 340 Healthcare peers.
34 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $29.87
- Nov 17, 2026
- Market cap
- $1.4B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 16.50 – 50.81
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 44/100
- Weak · 340 Healthcare peers
Industry: Drugs
UroGen Pharma Ltd scores 44/100. Weak. Quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 44 is built from 3 of 4 pillars, from 45% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=340Factor grades
Value omitted — no data yet.
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ~ Reversal Evidence
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeu…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Pacira BioSciences IncPCRX | 56 | $1.5B |
| Intellia Therapeutics IncNTLA | 41 | $1.4B |
| AlvotechALVO | 41 | $1.4B |
| AnaptysBio IncANAB | 53 | $1.4B |
| Novavax, Inc.NVAX | 37 | $1.3B |
| Taysha Gene Therapies IncTSHA | 58 | $1.3B |
| Ocular Therapeutix IncOCUL | 51 | $1.3B |
| Innoviva IncINVA | 73 | $1.3B |
| Absci CorpABSI | 39 | $1.3B |
| Mineralys Therapeutics IncMLYS | 55 | $1.3B |
Common questions
What sector and industry is UroGen Pharma in?
UroGen Pharma is in the Healthcare sector and the Drugs industry.
What is UroGen Pharma's Tenet Score?
UroGen Pharma's Tenet Score is 44 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




